Although for many decades bisphosphonates were used for adult bone loss, bisphosphonate administration in pediatric patients is new and was initiated in the past 15-year. The indications for pediatric bisphosphonates was extended to childhood malignancies with bone involvement, after additional effects were unveiled for bisphosphonates with recent research. In this article we review childhood b...

Osteoporosis is characterised by trabecular bone loss resulting from increased osteoclast activation and unbalanced coupling between resorption and formation, which induces a thinning of trabeculae and trabecular perforations. Bisphosphonates are the frontline therapy for osteoporosis, which act by reducing bone remodelling, and are thought to prevent perforations and maintain microstructure. H...

BACKGROUND Prognosis of traumatic osteonecrosis of femoral head in children is poor for either conservative treatment or surgical intervention. Intravenous bisphosphonate is an expecting medication to reduce femoral head resorption and to prevent femoral head collapse after traumatic osteonecrosis. This mechanism will reduce development of osteoarthritis and disability in the future. OBJECTIV...

PURPOSE The purpose of this study was to evaluate the effect of alendronates on bone remodeling around titanium implant in the maxilla of rats. MATERIALS AND METHODS The maxillary first molars were extracted and customized-titanium implants were placed immediately in thirty male Sprague-Dawley rats. The rats were divided into experimental (bisphosphonate) group and control group. At 4 weeks a...

Bisphosphonate is used widely for osteoporosis treatment, but a rising concern is the risk of osteonecrosis after long-term bisphosphonate use. Such cases are increasing, suggesting a need for research to prevent and treat bisphosphonate-related osteonecrosis of jaws. A 63-year-old female took bisphosphonate (Fosamax(®)) for four years for treatment of osteoporosis and stopped medication two mo...

Bisphosphonates are potent inhibitors of bone resorption and considered as a gold standard and are generally recommended as first-line therapy in patients with osteoporosis. Though bisphosphonates are shown to significantly reduce the risk of vertebral, non-vertebral and hip fractures, recent reports suggest a possible correlation between long-term bisphosphonate therapy and the occurrence of i...

Although the existence of atypical femoral fractures is well established and bisphosphonate therapy is thought to be a major risk factor, the underlying mechanisms are poorly understood. Epidemiological data show that atypical femoral fractures account for only a small proportion of diaphyseal subtrochanteric femoral fractures, being about 100 times less common than proximal femoral fractures. ...

Bisphosphonates are a class of agents used to treat osteoclast-mediated bone diseases and many neoplasm types. Osteonecrosis of the jaw is a common side effect of bisphosphonate therapy, presenting as exposed and necrotic maxillary and/or mandibular bone. In this report, we present a case of bisphosphonate-related osteonecrosis of the jaw in a patient who received oral alendronate therapy due t...

1168 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: fi ndings from the Women’s Health Initiative Rebecca L. Drieling, MPH, PhD, Andrea Z. LaCroix, PhD, MPH, Shirley A.A. Beresford, PhD, MS, Denise M. Boudreau, PhD, Charles Kooperberg, PhD, Rowan T. Chlebowski, MD, PhD, Margery Gass, MD, Carolyn J. Crandall, MD, MS, Catherine R. Womack,...

Cases of osteonecrosis of the jaw, insufficiency fractures and atypical low energy or atraumatic fractures of pelvis, femur (subtrochanteric/mid-shaft/distal-third), tibia, fibula, metatarsal, humerus, and ulna related to long-term bisphosphonate therapy have been reported in the literature. We present the case of an acute nontraumatic clavicle fracture, associated with long-term bisphosphonate...